Exclusive Market Insight & Professional Analysis: The most comprehensive resource center for the biotech industry

        Sign Up Today! Get started for all the insight you want!
  • Exclusive Posts

  • Industry Newsletters

  • Clinical Trials

  • Therapeutic Vaccines

  • Development-Stage Firm

  • Genomics

  • Gene Analysis

  • RNA Analysis

  • Possible Approvals

  • Stock Table

  • Possible Takeovers

  • Technology of the Week

  • Prohost Picks

  • And much more...

BIOTECHNOLOGY NEWS & COMMENTS

A New Option For Osteoporosis Treatment That Would Prevent Bone Fractures

  Tuesday, August 23, 2016

JAMA Publishes Positive Phase 3 Data for Abaloparatide in Postmenopausal Women with Osteoporosis More...

Is Advaxis Finally Running on the Right Track?

  Wednesday, August 17, 2016

Advaxis (ADXS) is a small clinical-stage biotech producing and developing cancer immunotherapy products based on its proprietary Lm Technology. The technology uses bioengineered live attenuated Listeria monocytogenes (Lm) bacteria. It is said that Adraxis therapeutics cancer immunotherapy agents are the first to generate cancer fighting T cells against cancer antigens in early testing. They could also neutralize myeloid-derived suppressor cells (MDSCs), which protect the tumor microenvironment from immunologic attack and contribute to tumor growth.  More...

Biotech Firms With Approaches Born To Stay and Succeed

  Wednesday, August 10, 2016

Immunotherapy More...

Why BMY News Is Not Bad As Hysterical Investors Believed

  Friday, August 05, 2016

ANOTHER MISLEADING STORY  More...

Adaptimmune EMA Privileges. Different Fate for Plummeting Stocks

  Monday, August 01, 2016

The EMA has created Priority Medicines (PRIME) regulatory initiative for products, which the European agency rules they are of unmet needs. PRIME makes them eligible for support, possible regulatory applications and potential accelerated reviews. PRIME has accepted Adaptimmune’s (ADAP) drug NY-ESO-targeting T-cell therapy. The drug became the 8th accepted for EMA’s PRIME program.   More...

Moderna Is a Private Revolutionary Biotech Firm That Investors Should Not Ignore

  Tuesday, July 26, 2016

We love to present to you Moderna, a firm that, we believe, is building revolutionary pipeline products. We mean it when we say revolutionary. The time has come for Moderna to be heard of by serious investors. It is still private, but it is revolutionary and is working with the publicly-traded firms AstraZeneca (AZN), Merck (MRK), and Vertex (VRTX) to bring what we believe will be game changing approaches for the management of intractable, untreatable and deadly diseases.   More...

NOVOCURE: The FDA Approves the Firm's Second Generation Non-Invasive Treatment for Glioblastoma

  Friday, July 15, 2016

News about approvals or insinuations about almost guaranteed future approvals of products that promise improving the management of chronic and life-threatening diseases are always welcomed with enthusiasm. Of course some approvals are more rewarding than others, which has to be assessed by investors. For the patients, however, any improvement, small or phenomenal is always considered good news.  More...

JUNO Surged After the FDA Removed the Clinical Hold of the ROCKET Trial. See Also: Why SAGE Surged

  Wednesday, July 13, 2016

JUNO   More...

Biotech Firms with Guaranteed Growth Potential

  Thursday, July 07, 2016

Good news is not always great news that makes a difference. In the drug industry, clinical trial results that demonstrate a drug has fulfilled the requirements of the trials, including the primary and secondary endpoints does not always guarantee that the drug will be successful if and when it hits the market. Experience and follow up on certain firms enables us to see the real light at the end of the tunnel, not just celebrate reaching the end of it without knowing what to expect outside. This makes a big difference.  More...

The Royal Divorce. Gilead Rallied Not Plummeted

  Wednesday, June 29, 2016

The Royal Divorce More...

Join our FREE Email Updates, with the latest insight information about the biotech industry